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We evaluated the association of indices of paraoxonase (PON1) and oxidative status with subclinical cardiovascular disease (CVD)
inmixed-ancestry SouthAfricans. Participantswere 491 adults (126men)whowere stratified by diabetes status and bodymass index
(BMI). Carotid intima-media thickness (CIMT) was used as a measure of subclinical CVD. Indices of PON1 and oxidative status
were determined by measuring levels and activities (paraoxonase and arylesterase) of PON1, antioxidant activity (ferric reducing
antioxidant power and trolox equivalent antioxidant capacity), and lipid peroxidation markers (malondialdehyde and oxidized
LDL). Diabetic subjects (28.9%) displayed a significant decrease in PON1 status and antioxidant activity as well as increase in
oxidized LDL and malondialdehyde. A similar profile was apparent across increasing BMI categories. CIMT was higher in diabetic
than nondiabetic subjects (𝑃 < 0.0001) but showed no variation across BMI categories. Overall, CIMT correlated negatively with
indices of antioxidant activity andpositivelywithmeasures of lipid oxidation. Sex, age, BMI, anddiabetes altogether explained 29.2%
of CIMT, with no further improvement from adding PON1 and/or antioxidant status indices.Though indices of PON1 and oxidative
status correlate with CIMT, their measurements may not be useful for identifying subjects at high CVD risk in this population.
1. Introduction
Early identification of people at high risk of atherosclerotic
cardiovascular diseases (CVDs), followed by the implementa-
tion of lifestyle and drug interventions with proven beneficial
effects, has been largely emphasized in strategies to reduce
the mortality and morbidity from cardiovascular disease [1].
This is particularly relevant in some individuals including
diabetic or obese people in whom risk factors for CVD tend
to cluster and confer a very high risk of CVD [2]. Indeed,
compared with their nondiabetic counterparts, people with
type 2 diabetes have 2–6-fold higher risk for future CVD
which accounts for up to 75% of mortality in this popula-
tion [3]. The relation between adiposity and cardiovascular
health was for a long time thought to be mediated solely
by coincident CVD risk factors [4]. Several studies have
however shown that obesity not only relates to but also
independently predicts CVD [5, 6]. Nonetheless, there is
no denying of the correlation between diabetes and obesity.
Both conditions are increasingly viewed as proinflammatory
states associatedwith an alteredmetabolic profile, endothelial
dysfunction, and oxidative stress [5, 6]. Oxidative stress has
been hypothesized as a mechanism linking the two condi-
tions as well as accounting for their initiation, progression,
and possible link with early atherosclerosis [5, 6]. It is
plausible therefore that the association between increased
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bodymass index (BMI) and diabetes and early atherosclerosis
is largely due to underlying oxidative stress. The present
study was undertaken to evaluate our hypothesis that specific
indices of oxidative stress are associated with markers of
subclinical CVD and may aid early CVD risk stratification
in a population with a high prevalence of diabetes and
obesity. For this purpose, indices of PON1 and oxidative
status were determined by measuring levels and activities
(paraoxonase and arylesterase) of paraoxonase (PON) 1,
antioxidant activity (ferric reducing antioxidant power and
trolox equivalent antioxidant capacity), and lipid peroxi-
dation markers (malondialdehyde and oxidized LDL). The
association of subclinical atherosclerosis with PON1 activity
and oxidative stress has been reported in previous studies
[7, 8]. Similar to the increasing rates of CVDworldwide, CVD
contributes significantly to the public health burden in South
Africa where interethnic differences in CHD prevalence
and mortality are apparent [9]. The mixed ancestry is a
heterogeneous South African ethnic group with a high risk
for CVD demonstrated by very high prevalence of obesity,
diabetes, and metabolic syndrome [10, 11]. Furthermore, we
had also demonstrated high lifetime CVD risk in mixed-
ancestry subjects with normoglycemia and those younger
than 35 years [11].
2. Materials and Methods
2.1. Study Setting and Population. The study setting has been
described in detail elsewhere [10, 11] and is located in a
mixed-ancestry township (Bellville South) located within
the Northern suburbs of Cape Town, Western Cape, South
Africa. The mixed ancestry is a heterogeneous South African
population comprising 32–43% Khoisan, 20–36% Bantu-
speaking African, 21–28% European, and 9–11% Asian ances-
try [12]. This specific study involved participants that took
part in the survey during January 2011–November 2011. The
study was approved by the research ethics committees of Stel-
lenboschUniversity (ReferenceNumber: N10/04/118) and the
Cape Peninsula University of Technology (CPUT/HW-REC
2010/H017). The study was conducted according to the Code
of Ethics of the World Medical Association (Declaration of
Helsinki). All participants signed written informed consent
after all the procedures were fully explained in the language
of their choice.
2.2. Clinical Data. All consenting participants completed a
questionnaire designed to obtain information on lifestyle
factors such as smoking and alcohol consumption, physi-
cal activity, diet, family history of CVD, diabetes mellitus,
and demographics. Blood pressure measurements were per-
formed according to theWorld Health Organization (WHO)
guidelines [13] using a semiautomatic digital blood pressure
monitor (Rossmax, PA, USA) on the right arm in a sitting
position. Other clinical measurements included the body
weight, height, waist, and hip circumferences. Weight (to
the nearest 0.1 kg) was determined in a subject wearing light
clothing and without shoes and socks, using a Sunbeam
EB710 digital bathroom scale, which was calibrated using
a standard object of known mass. Waist circumference was
measured using a nonelastic tape at the level of the narrowest
part of the torso, as seen from the anterior view. The hip
circumference was also measured using a nonelastic tape
around the widest portion of the buttocks. All anthropo-
metric measurements were performed three times and their
average was used for analysis. Diabetes status was based
on a history of doctor diagnosis, a fasting plasma glucose
≥7.0mmol/L, and/or a 2-hour postoral glucose tolerance
test (OGTT) plasma glucose >11.1mmol/L as recommended
by the WHO [14]. Adiposity was described according to
body mass index (BMI in kg/m2) as normal weight (<25),
overweight (25–30), and obese (>30).
2.3. Measurement of Carotid Intima-MediaThickness (CIMT).
Two qualified sonographers measured CIMT in longitudinal
section at the far wall of the distal common carotid arteries,
2 cm from the bifurcation, at 3 consecutive end-points, 5–
10mm apart. The mean of six readings (3 from each side)
was calculated for each participant using a portable B-
mode and spectral Doppler ultrasound scanner equipped
with cardiovascular imaging software. The GE LOGIQ e
(General Electric Healthcare, Germany) high performance
multipurpose colour compact ultrasound system included
new imaging CrossXBeam technologies with multifrequency
virtual apex on phased array cardiac transducer (3S-RS wide
band phased probe 1.7–4.0MHz) for echocardiography and
a linear wideband vascular transducer (8L-RS 4.0–12MHz
linear probe) used for improved diagnostic confidence and
imaging clarity for the carotids.
2.4. LaboratoryMeasurements. Blood samples were collected
after an overnight fast and processed for further biochemical
analyses. The Cobas 6000 immunometric analyzer (Roche
Diagnostics) was used tomeasure levels of fasting plasma glu-
cose (FBG), glycated haemoglobin (HbA1c), total cholesterol,
high density lipoprotein cholesterol (HDL-c), triglycerides
(TG) and 𝛾-glutamyltransferase (GGT), and high sensitive C-
reactive protein (hsCRP). Low density lipoprotein cholesterol
(LDL-c) was calculated using Friedewald’s formula [15]. An
enzyme linked immunosorbent assay (ELISA) kit was used
to measure plasma levels of paraoxonase 1 (PON1) following
the manufacturer’s instructions (Aviscera biosciences, Santa
Clara, California). This assay employs a quantitative sand-
wich enzyme immunoassay technique.
2.5. Total Antioxidant Capacity. The total antioxidant capac-
ity in plasma samples was assessed using the ferric reducing
antioxidant power (FRAP) and trolox equivalent antioxidant
capacity (TEAC) assays. FRAP was done according to the
method of Benzie and Strain [16]. Briefly, plasma samples
were mixed with FRAP reagent, incubated for 30min at
37∘C, and the absorbance at 593 nm was recorded using a
spectrophotometer (Spectramax plus384 Molecular devices,
USA). The TEAC assay was according to Re et al. [17]
and is based on monitoring (at 734 nm) the oxidation of 2,
2󸀠-azinobis-(3-ethylbenzothiazoline-6-sulfonic acid) radical
(ABTS) cation formed by reacting ABTS, and potassium
persulfate. Distilled water was used instead of PBS to dilute
the ABTS+ radical solution.
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2.6. Paraoxonase Activity. Paraoxonase (PONase) and aryles-
terase (AREase) activities weremeasured using paraoxon and
phenylacetate (Sigma Aldrich, SA) as substrates, respectively.
PONase activity was measured using Richter and Furlong’s
method [18] from the initial velocity of p-nitrophenol pro-
duction at 37∘C and the increased absorbance at 405 nm
wasmonitored on a spectrophotometer (Spectramax plus384,
Molecular devices, USA). Each serum sample was incubated
with 5-mmol/L eserine (Sigma Aldrich, SA) for 15 minutes
at room temperature to inhibit serum cholinesterase activity
which is usually elevated in diabetes and would otherwise
interfere with the determination of paraoxonase activity in
serum from diabetic individuals. PON-1 activity of 1 U/L was
defined as 1 𝜇mol of p-nitrophenol hydrolyzed per minute.
A slightly modified method of Browne et al. [19] was used
to measure AREase activity. The working reagent consisted
of 20mmol/L Tris-HCl, 4mmol/L phenyl acetate, pH 8.0,
with 1.0mmol/L CaCl
2
(Sigma Aldrich, SA). The reaction
was initiated by adding 5 𝜇L of 40-fold tris-diluted samples
to 345 𝜇L of the working reagent at 25∘C. The change in
absorbance at 270 nmwas recorded for 60minutes after a 20-
second lag time on a Spectramax plus384 spectrophotometer.
The activity, expressed as kU/L, was based on the molar
absorptivity (1310) of phenol at 270 nm. In both assays, the
rates used to generate the data points were derived from the
linear portions of the rate versus time plots.
2.7. Lipid Peroxidation. Plasma MDA and ox-LDL were used
as markers of lipid peroxidation (LPO). The method of Jent-
zsch et al. [20] was used to estimate the thiobarbituric acid
reactive substances (TBARS) which reflect the production of
MDA. Plasma ox-LDLs were measured using a quantitative
sandwich ELISA kit (Cellbiolabs, San Diego, California).
2.8. Statistical Analyses. Data are presented asmean standard
deviation, SD, or median of 25th–75th percentiles for con-
tinuous variables and as count and percentage for categorical
variables. For group (sex, diabetes status, and BMI, quarters
of CIMT) comparisons, chi square test, student’s 𝑡-test, and
analysis of the variance (ANOVA) and nonparametric equiv-
alents were used. Continuous associations between CIMT
and the indices were assessed graphically with the use of
correlation matrix, before and after applying the Box-Cox
[21] power transformations to improve the shape of the asso-
ciations; then the “Covariance Estimation for Multivariate 𝑡
Distribution” [22] method was used to derive the correlation
coefficients, whileminimizing the potential effects of outliers.
The Steiger 𝑡-test was used to compare correlation coefficients
among indices. Regression coefficients to indicate the size
of the association of each of the indices with CIMT were
derived from robust multiple linear regression models that
included each of the 4 variables of interest, age, sex, body
mass index, and diabetes status. Analyses were carried out
using R statistical software version 3.0.0 [03-04-2013], (The R
Foundation for Statistical Computing, Vienna, Austria). The
significance level was set at 0.05.
3. Results
3.1. Participants’ Basic Profile. Of the 651 participants (men
170, 26%)who took part in the study, 160 (25%)were excluded
from this analysis as they had missing values for CIMT
and/or other relevant variables. Baseline characteristics of
participants included and excluded from analyses were very
similar. The final analytic sample comprised 491 participants
(men 126, 25.7%) with amean age of 54.6 (13.2) years. Among
them, 142 (29%) had diabetes, 137 (28%) were overweight,
and 261 (53%) were obese. The average BMI was 31.4 (8.1)
kg/m2 (Table 1). There were no age differences between men
and women and across the BMI profiles but diabetic subjects
were significantly older than nondiabetic ones (59.6 versus
52.5 years, 𝑃 < 0.0001) and had higher BMI (33.4 versus
30.6 kg/m2, 𝑃 = 0.002). Women had significantly higher
levels of HbA1c, BMI, and waist circumference. In general,
there were no differences between the genders with regard
to the lipid profile. Triglyceride levels increased while HDL-
cholesterol decreased across BMI categories (both 𝑃 <
0.0001, ANOVA).
3.2. Paraoxonase and Oxidative Status Profile. Men had
significantly higher FRAP (732 versus 655 𝜇M, 𝑃 = 0.006)
and ox-LDL (5141 versus 4110 ng/mL, 𝑃 < 0.0001) and
lower AREase activity and PON 1 levels (91 versus 117 kU/L;
88 versus 98 𝜇g/mL, 𝑃 < 0.0001) respectively, compared
to women. In diabetic subjects, a less favorable profile was
observed for PON1 (mass and activity) and oxidative status
(decreased FRAP and TEAC; elevated Ox-LDL and TBARS).
A similar less favorable profile was also apparent across
increasing BMI categories (Table 1).
3.3. CIMT Profile and Associations with PON1 and Oxidative
Profiles. The median CIMT was 0.82mm. It was higher in
men than in women (0.95 versus 0.80mm, 𝑃 < 0.0001) and
in diabetic than in nondiabetic subjects (0.98 versus 0.77mm,
𝑃 < 0.0001). However, there was neither a significant
difference (𝑃 > 0.227) nor a linear trend in the distribution of
CIMT levels across BMI categories (Table 1). Overall, CIMT
correlated negatively with all indices of antioxidant activity
and positively with the measures of lipid oxidation (Table 2,
Figure 1). Correlation coefficients however were very weak,
with borderline significant differences by diabetes status for
the correlations of CIMT with TEAC (𝑃 = 0.04), Ox-LDL
(𝑃 = 0.02), and TBARS (𝑃 = 0.04). In stratified analyses, the
correlation coefficients for each of these three indices always
appeared to be significant and stronger in nondiabetics and
weak and nonsignificant in diabetics (Table 2, Figure 1). The
distribution of participants’ characteristics across quarters of
CIMT is shown in Table 3 showing increasing age, systolic
blood pressure, waist/hip ratio, fasting glucose, total choles-
terol, and decreasing proportion of women across increasing
quarters of CIMT.
3.4. Multivariable Analysis. In a model comprising sex, age,
and BMI, each of the three variables was significantly asso-
ciated with CIMT. This basic model explained 26.4% of the
variation in CIMT levels. When this model was expanded
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Figure 1: Correlations of paraoxonase, paraoxonase activity, arylesterase ferric reducing antioxidant power, TEAC, oxidized LDL, and
thiobarbituric acid reactive substances activity with carotid intima-media thickness. Participants are grouped by diabetes status with the
triangles representing those with diabetes and the solid circles representing those without diabetes.The superimposed regression lines are for
the overall sample (solid line), and participants with (broken line) andwithout diabetes (dotted lines). Accompanying correlations coefficients
are shown in Table 2.
with the inclusion of diabetes status, all variables in themodel
remained significantly associated with CIMT and further
explained 29.2% of the variation. However, as shown in
Table 4, none of the indices of PON1 and antioxidant status
significantly associated with CIMT in the presence of the four
basic variables and furthermore did not improve the fit of
models in predicting the variability of CIMT. In the presence
of variables in the basic model, SBP (𝛽 = 0.002, 𝑃 < 0.0001),
but not DBP (𝛽 = 0.001, 𝑃 = 0.066), was significantly
associated with CIMT. In the same basic model, neither waist
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Table 2: Robust correlation of CIMT with PON and antioxidant status.
Correlates Overall No diabetes Diabetes 𝑃 value
PON1 −0.09 (−0.17 to 0.00) −0.04 (−0.14 to 0.07) −0.01 (−0.17 to 0.16) 0.74
PONase −0.17 (−0.25 to −0.08) −0.11 (−0.21 to 0) 0.04 (−0.13 to 0.20) 0.15
AREase −0.24 (−0.32 to −0.15) −0.20 (−0.30 to −0.09) −0.05 (−0.21 to 0.12) 0.13
FRAP −0.17 (−0.26 to −0.09) −0.12 (−0.22 to −0.02) 0.03 (−0.13 to 0.20) 0.12
TEAC −0.22 (−0.30 to −0.13) −0.16 (−0.26 to −0.06) 0.04 (−0.12 to 0.21) 0.04
Ox-LDL 0.25 (0.17 to 0.34) 0.21 (0.10 to 0.30) −0.03 (−0.20 to 0.13) 0.02
TBARS 0.26 (0.17 to 0.34) 0.19 (0.09 to 0.29) −0.01 (−0.17 to 0.16) 0.04
Paraoxonase 1; PONase: paraoxonase; AREase: arylesterase; FRAP: ferric reducing ability of plasma; TEAC: trolox equivalent antioxidant capacity; Ox-LDL:
oxidized LDL; TBARS: thiobarbituric acid reactive substances.
Table 3: Characteristics of the participants by quarters of CIMT.
Variables Quartiles of CIMT 𝑃 value
Q1 Q2 Q3 Q4
𝑁 123 131 118 119 NA
CIMT [min–max] 0.30–0.67 0.68–0.82 0.83–1.02 1.03–2.18 NA
Female, 𝑛 (%) 101 (82.1) 104 (79.4) 97 (82.2) 63 (52.9) <0.0001
Age (years) 44.9 (12.9) 53.3 (11.8) 57.6 (11.3) 63.0 (9.8) <0.0001
BMI (kg/m2) 30.5 (6.7) 31.5 (8.0) 32.3 (8.0) 31.5 (9.5) 0.234
Waist circumference (cm) 94.0 (18.7) 97.1 (13.5) 96.3 (14.0) 98.2 (14.9) 0.060
Waist/hip ratio 0.86 (0.15) 0.87 (0.12) 0.89 (0.10) 0.93 (0.10) <0.0001
Systolic BP (mmHg) 125 (19) 135 (26) 138 (21) 149 (31) <0.0001
Diastolic BP (mmHg) 78 (12) 83 (16) 82 (11) 84 (15) 0.007
FPG (mmol/L) 5.7 (2.2) 6.0 (2.3) 6.4 (2.8) 7.6 (3.9) <0.0001
HbA1c (%) 6.2 (1.1) 6.2 (1.0) 6.7 (1.6) 7.4 (2.3) <0.0001
Creatinine (𝜇M) 68.8 (14.3) 72.8 (19.0) 72.2 (18.6) 85.8 (39.8) <0.0001
C-reactive protein (mg/L) 4.4 [1.4–7.6] 5.1 [2.2–8.7] 5.4 [2.5–9.2] 5.3 [2.0–9.2] 0.222
GGT (IU/L) 24 [17–38] 29 [19–49] 28 [19–41] 29 [21–43] 0.145
Total cholesterol (mmol/L) 5.2 (0.9) 5.4 (1.1) 5.7 (1.2) 5.7 (1.1 ) <0.0001
HDL cholesterol (mmol/L) 1.4 (0.4) 1.3 (0.4) 1.4 (0.4) 1.4 (0.4) 0.708
LDL cholesterol (mmol/L) 3.2 (0.8) 3.4 (1.0) 3.6 (1.0) 3.6 (1.0) 0.003
Triglycerides (mmol/L) 1.3 (0.7) 1.5 (0.9) 1.7 (1.0) 1.6 (0.9) 0.0008
PON1 (𝜇g/mL) 102 [78–112] 94 [77–110] 98 [77–112] 94 [70–110] 0.290
PONase (U/L) 204 [170–233] 184 [130–215] 182 [136–218] 177 [119–217] 0.005
AREase (kU/L) 118 [97–141] 103 [84–126] 94 [75–132] 95 [76–120] <0.0001
FRAP (𝜇M) 734 [602–887] 672 [573–809] 636 [533–795] 667 [534–785] 0.014
TEAC (nM) 1484 [1068–1858] 1316 [947–1628] 1206 [929–1595] 1235 [904–1568] 0.001
Ox-LDL (ng/mL) 3618 [2641–5102] 4576 [3230–5844] 4747 [3638–6176] 4975 [3545–6333] <0.0001
TBARS (nM) 1857 [1251–2504] 2280 [1544–3042] 2447 [1919–3256] 2571 [1905–3666] <0.0001
FPG: fasting plasma glucose; BMI: body mass index; BP blood pressure; GGT: gamma glutamyl transferase; HDL: high density lipoprotein; LDL: low density
lipoprotein; CIMT: carotid intima-media thickness; PON1: paraoxonase 1; PONase: paraoxonase; AREase: arylesterase; FRAP: ferric reducing ability of plasma;
TEAC: trolox equivalent antioxidant capacity; Ox-LDL: oxidized LDL; TBARS: thiobarbituric acid reactive substances.
circumference (𝛽 = −0.0007, 𝑃 = 0.434) nor waist/hip ratio
(𝛽 = 0.031, 𝑃 = 0.724) was associated with CIMT, even
when they were allowed to replace BMI in the model (both
𝑃 >= 0.364).
4. Discussion
The prominent role of oxidative stress in the occurrence
of atherosclerosis and related complications is well rec-
ognized, with suggestions that measurement of oxidative
stress may aid risk stratification and effective prevention
of atherothrombotic diseases. In this study, we evaluated
the profile of several indices of PON1 and oxidative status
and their relationship with CIMT, which is a marker of
subclinical cardiovascular disease. Our findings demonstrate
that measures of oxidative stress together with PON1 are only
superficially associated with CIMT. Instead, conventional
risk factors such as age, gender, adiposity, and chronic
hyperglycemia and not measures of oxidative stress may be
more important in estimating CVD risk in our population.
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The physiological role of PON1 in reducing atheroscle-
rosis stems from its ability to inhibit the oxidation of low
density lipoprotein (LDL) [23] and its ability to stimulate
cholesterol efflux from macrophages [24]. In this regard,
decreased activities of PON1 and/or other antioxidant species
have been demonstrated in obesity, diabetes, and other
oxidative stress-related conditions [25–27]. In our study, we
found PON1 activities to be significantly reduced in obese
and diabetic subjects. It has previously been suggested that
decreased PON1 activity in diabetes may be due to glycation-
induced changes to HDL and/or PON1, thereby affecting its
association with HDL that has been related to its antiathero-
genic properties [28]. Similar to diabetes, obesity is strongly
associated with oxidative stress and proinflammatory state
which in this study is corroborated by significantly raised
oxidative stress markers (ox-LDL and TBARS) in obese
subjects.
Proinflammatory markers and oxidative stress have
been shown to modulate and inactivate PON1 activity
[29–32]. Adipose tissue expresses inflammatory cytokines,
interleukin-6 (IL-6), and tumor necrosis factor-𝛼 (TNF-𝛼)
which are associated with oxidative stress [33]. In a study
which introduced a mixture of IL-6, IL-1, and TNF-𝛼 in
murine hepatoma cell line Hepa 1–6, a reduction in PON1
mRNA was observed [29]. In addition, obesity alters the
composition of HDL in a manner that may impair binding
of PON1 to HDL surface such as lowering both HDL’s largest
subfraction (HDL2) and its major binding protein (apo
A1) [34]. Since PON1 is a lipid-dependent enzyme whose
activity hinges on its conformationwithinHDL, the impaired
binding in results decreased enzyme activity.
Measurements of oxidative stress have previously been
proposed as a predictor of atherosclerosis in end stage
renal disease patients [7]. In their study, Dursan et al. [7]
demonstrated significant positive correlation between CIMT
and serum TBARS and nitrite/nitrate levels and a significant
negative correlation between CIMT and antioxidant markers
superoxide dismutase (SOD), catalase (CAT), and plasma
sulfhydryl (P-SH) levels in patients on chronic haemodialysis.
We found total antioxidants (FRAP, AREase) to be negatively
correlated with CIMT, whilst markers of oxidative stress (ox-
LDL and TBARS) showed a positive correlation, but the
association was not retained in further adjusted regression
analyses and there were suggestions that diabetes affects these
associations since theywere generally stronger and significant
in nondiabetics compared to diabetics. Instead, traditional
CVD risk factors, age, gender, obesity, and diabetes, were sig-
nificant determinants of subclinical atherosclerosis, account-
ing for 29.2% of CIMT variability. Previous studies have
demonstrated that only a fraction of CVD risk is explained by
traditional risk factors [35, 36] prompting a search for alter-
nate and additional predictors. Emerging data from around
the world support the pivotal role of chronic inflammation in
the occurrence of CVD complications. Although influences
of PON1 and oxidative stress have been demonstrated to be
on the early steps of atherosclerosis [37], our results exclude
measurements of PON1 activity and indices of antioxidant
status in prediction of atherosclerotic risk.
Some limitations should be accounted for when inter-
preting our findings. First, the cross-sectional design of our
study precludes drawing inferences on the direction of the
associations. Second, we did not establish the intraobserver
variability between the sonographers who performed CIMT
measurements; however we used multiple measurements at
different points. Third, because our study population was
ethnically exclusive, our results can only be generalized to
mixed-ancestry South African subjects. Fourth, we used
BMI as the marker of obesity although it cannot distinguish
between visceral and subcutaneous fat. Visceral fat is partic-
ularly strongly associated with atherosclerotic CVD risk [38].
Fifth, we did not evaluate other residual confounders that
may affect oxidative stress markers such as dietary factors.
Lastly, the number of males versus that of females is skewed,
with this being a common trend in South African population
studies. Nonetheless, we used two methods for each of the
three measures of oxidative status. Besides allowing us to
demonstrate the consistency of our findings, this approach
reinforces the accuracy of antioxidant status results since
the measured total antioxidant status of biological samples
is known to be method specific [39]. Furthermore, the
nonspecific nature of the MDA-TBARS method requires
corroboration. Since PON1 is purported to function as an
antioxidant, another key strength distinguishing this study
from several others is the evaluation of its activity in the
context of antioxidant status.
In conclusion, although atherosclerosis is considered an
inflammatory/oxidative condition, our results argue against
a major role of PON1 and oxidative status in prediction
of atherosclerotic risk as none of these indices impacted
on the model’s value in explaining the variability of CIMT.
Rather, the findings reaffirm the importance of conventional
risk factors such as age, gender, adiposity, and chronic
hyperglycemia in estimatingCVD risk in thismixed-ancestry
population.
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